Madrigal Pharmaceuticals
MDGL
109 hedge funds and large institutions have $741M invested in Madrigal Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 46 increasing their positions, 27 reducing their positions, and 25 closing their positions.
70% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 27
3.99% more ownership
Funds ownership: 67.88% → 71.87% (+4%)
9% less funds holding
Funds holding: 120 → 109 (-11)
22% less capital invested
Capital invested by funds: $954M → $741M (-$213M)
36% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 25
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
81% less call options, than puts
Call options by funds: $1.71M | Put options by funds: $9.11M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$27.5M |
| 2 |
HM
HealthCor Management
New York
|
+$26.2M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.57M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$4.93M |
| 5 |
AC
Armistice Capital
New York
|
+$4.67M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
-$12.4M |
| 2 |
LM
Luminus Management
Houston,
Texas
|
-$11.2M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$6.93M |
| 4 |
HI
HBK Investments
Dallas,
Texas
|
-$6.83M |
| 5 |
ECM
Element Capital Management
New York
|
-$5.04M |
MDGL Hedge Fund Activity: Q1 2020 in Review
109 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q1 2020, worth a combined $741M — down 22% from $954M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of MDGL and 16 opened new positions — a net loss of 9 holders — while 27 trimmed existing stakes and 46 added.
The largest buyer was Baker Bros. Advisors, adding an estimated $27.5M. The largest seller was Laurion Capital Management, exiting entirely with an estimated $12.4M sold.
- 109 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q1 2020, down from 120 in Q4 2019.
- Funds reported $741M of Madrigal Pharmaceuticals stock for Q1 2020, down 22% quarter-over-quarter.
- 16 funds opened new Madrigal Pharmaceuticals positions in Q1 2020 and 25 closed out, a net change of -9 holders.
- The largest Madrigal Pharmaceuticals buyer in Q1 2020 was Baker Bros. Advisors, an estimated $27.5M added.
- The largest Madrigal Pharmaceuticals seller in Q1 2020 was Laurion Capital Management, an estimated $12.4M sold.
Based on aggregated 13F filings for Q1 2020.